Medistim announces that they have received confirmation from its distributor in Japan that its newest product MiraQ™ is now approved for sale.
MiraQ is Medistim’s newest generation of products for quality assurance within vascular and cardiac surgery. The system is based on ultrasound, and combines blood flow measurement through transit time flow measurement (TTFM) and high frequency ultrasound imaging (HFUS). Medistim’s unique TTFM and HFUS combination provides guidance and control during surgery, in order to avoid or correct issues intraoperatively.
Medistim is now in position to sell MiraQ in all major markets except Canada where an application is in process.
Japan is a substantial market for Medistim with about 400 hospitals performing on average 14 000 cardiac procedures per year. Medistim’s equipment is used in more than 80 % of the procedures. It is expected that a large portion of existing users over time will purchase the new product MiraQ. Medistim’s products are well accepted in the Japanese market and the company is optimistic with regard to future sales of MiraQ in Japan.
Read more about MiraQ here